Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab + ART for HIV Remission
NCT03577782Phase 2Unknown
- Sponsor
- Hospital Universitario Virgen del Rocío
- Start
- Sep 2018
- Primary completion
- May 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vedolizumab in human immunodeficiency virus infection (HIV), sponsored by Hospital Universitario Virgen del Rocío. Primary endpoints: Number of participants with treatment-related adverse events at 48 weeks and Plasma viral load rebound or remission after interrupting Vedolizumab infusions and ART at 48 weeks. Status: unknown.
02
Drugs
vedolizumab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03577782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577782.